Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

被引：0
|
作者：
Kristian Reich
Luca Bianchi
Abdallah Khemis
Julia-Tatjana Maul
Athanasios Tsianakas
Christoph M. Schempp
Kim Petersen
Mia M. Noergaard
Lluis Puig
机构：
[1] University Medical Center Hamburg-Eppendorf,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata,Department of Dermatology, Polyclinique Saint George
[3] Groupe KANTYS,Department of Dermatology
[4] University Hospital of Zürich,Faculty of Medicine
[5] University of Zürich,Department of Dermatology
[6] Fachklinik Bad Bentheim,Department of Dermatology, Faculty of Medicine, Medical Center
[7] University of Freiburg,Department of Dermatology, Hospital de la Santa Creu i Sant Pau
[8] LEO Pharma A/S,undefined
[9] Autonomous University of Barcelona,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷
关键词：
Brodalumab; Guselkumab; Plaque psoriasis; PASI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：453 / 468
页数：15
相关论文
共 50 条
  • [1] Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
    Reich, Kristian
    Bianchi, Luca
    Khemis, Abdallah
    Maul, Julia-Tatjana
    Tsianakas, Athanasios
    Schempp, Christoph M.
    Petersen, Kim
    Noergaard, Mia M.
    Puig, Lluis
    DERMATOLOGY AND THERAPY, 2024, 14 (02) : 453 - 468
  • [2] Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
    Langley, R. G.
    Tsai, T. -F.
    Flavin, S.
    Song, M.
    Randazzo, B.
    Wasfi, Y.
    Jiang, J.
    Li, S.
    Puig, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 114 - 123
  • [3] Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
    Hampton, Philip
    Borg, Emma
    Hansen, Jes Birger
    Augustin, Matthias
    PSORIASIS-TARGETS AND THERAPY, 2021, 11 : 123 - 131
  • [4] Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)
    Paul, C.
    Puig, L.
    Kragballe, K.
    Luger, T.
    Lambert, J.
    Chimenti, S.
    Girolomoni, G.
    Nicolas, J. -F.
    Rizova, E.
    Lavie, F.
    Mistry, S.
    Bergmans, P.
    Barker, J.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 425 - 434
  • [5] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    Papp, K. A.
    Reich, K.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Krueger, J. G.
    Russell, C. B.
    Milmont, C. E.
    Li, J.
    Klekotka, P. A.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286
  • [6] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [7] IXEKIZUMAB PROVIDES GREATER CUMULATIVE BENEFITS VERSUS USTEKINUMAB OVER 24 WEEKS FOR PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN A RANDOMIZED, DOUBLE-BLIND PHASE 3B CLINICAL TRIAL
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Henneges, Carsten
    Shen, Wei
    Shrom, David
    Dossenbach, Martin
    Pinter, Andreas
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 55 - 56
  • [8] Ixekizumab provides greater cumulative benefits versus ustekinumab over 24 weeks for patients with moderate-to-severe psoriasis in a randomized double-blind phase 3b clinical trial
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Henneges, Carsten
    Shen, Wei
    Shrom, David
    Dossnbach, Martin
    Pinter, Andreas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB173 - AB173
  • [9] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
  • [10] Intramuscular versus oral dexamethasone for the treatment of moderate-to-severe croup: A randomized, double-blind trial
    Donaldson, D
    Poleski, D
    Knipple, E
    Filips, K
    Reetz, L
    Pascual, RG
    Jackson, RE
    ACADEMIC EMERGENCY MEDICINE, 2003, 10 (01) : 16 - 21
12345